The publication of this infographic was sponsored by Menarini Stemline and is based on a symposium presented at the European Society for Medical Oncology (ESMO) Congress 2024.
This infographic presents data from the EMERALD trial of elacestrant versus standard-of-care therapy in these patients, demonstrating that:
- elacestrant significantly prolonged progression free survival (PFS) with a manageable safety profile versus standard-of-care endocrine therapy (ET); and
- a longer duration of prior ET + CDK4/6i in advanced breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared to ET, being consistent across all clinical subgroups with ESR1-mutated tumors. Elacestrant monotherapy is approved and recommended as second-line therapy for patients with ER+/HER2- advanced breast cancer and ESR1 mutations, based on data from the EMERALD Phase III trial.
For further data on unmet needs in second-line therapy for ER+/HER2- advanced breast cancer, view our infographic here.
For further data on ESR1 mutation testing in ER+/HER2- advanced breast cancer, view our infographic here.
